ERBB2 and breast cancer: In patients with HR+BC, HER2-low status showed a better prognosis as compared to the patients with HER2-ultralow and HER2+ BC (RFS and DMFS P = .0048 and P = .0015, respectively), while there was no prognostic effect of HER2 expression in the HR− subgroups.